Table 4 Characteristics of epithelial ovarian cancer patients in the validation cohort
From: Whole exome sequencing-based homologous recombination deficiency test for epithelial ovarian cancer
Validation group | Â | Â |
|---|---|---|
WES-based scarHRD test | Positive | Negative |
Number of patients | 12 | 11 |
Age (years old) | 57.5(46–77) | 64(28–74) |
Pretreatment CA-125 (U/ml) | 1211 (375- 10000) | 1206 (227-17750) |
Histology: Serous carcinoma | 12(100%) | 11(100%) |
FIGO stage: Advanced | 12(100%) | 11(100%) |
Tumor grade: high | 12(100%) | 11(100%) |
Debulking surgery | Â | Â |
 R0 | 3(25%) | 6(54.5%) |
 R1 | 6(50%) | 3(27.3%) |
 R2 | 3(25%) | 2(18.2%) |
Platinum response | Â | Â |
 Sensitive | 12(100%) | 3(27.2%) |
 Resistant | 0(0%) | 4(36.4%) |
 N.A. | 0(0%) | 4(36.4%)* |
Patient numbers with PARPi | 6(50%) | 5(45.5%) |
PARPi interval (months) | 17(9–22) | 3(2–8) |
Recurrence | Â | Â |
 Yes | 8(66.7%) | 5(45.5%) |
 No | 4(33.3%) | 6(54.5%) |
Progression free survival (months) | 14.5(8–24) | 4(0–9) |